EUVIMEDEUVIMED entdecken
Crossref

Clinical manifestations and prognosis of immune-mediated membranous nephropathy concurrent with other glomerulonephritides: A retrospective Chinese cohort analysis

Zhe Li, Shuhua Zhu, Ke Zuo, Dacheng Chen, Weibo Le, Feng Xu, Xia Wang

Clinical Nephrology · 2025

DOI: 10.5414/cn111627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Zhe Li und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Glomerulonephritis, Glomerulonephritis, IGA, Glomerulonephritis, Membranous.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesGlomerulonephritisGlomerulonephritis, IGAGlomerulonephritis, MembranousGlomerulosclerosis, Focal SegmentalAdultFemaleHumansMaleMiddle AgedAutoantibodiesBiopsyChinaKidneyPrognosisReceptors, Phospholipase A2Retrospective StudiesEast Asian People

Substanzen

AutoantibodiesPLA2R1 protein, humanReceptors, Phospholipase A2

Zitieren

APA

Li, Z., Zhu, S., Zuo, K., Chen, D., Le, W., Xu, F., & Wang, X. (2025). Clinical manifestations and prognosis of immune-mediated membranous nephropathy concurrent with other glomerulonephritides: A retrospective Chinese cohort analysis. Clinical Nephrology. https://doi.org/10.5414/cn111627

Vancouver

Li Z, Zhu S, Zuo K, Chen D, Le W, Xu F, et al. Clinical manifestations and prognosis of immune-mediated membranous nephropathy concurrent with other glomerulonephritides: A retrospective Chinese cohort analysis. Clinical Nephrology. 2025. doi:10.5414/cn111627

BibTeX
@article{Li2025,
  author = {Li, Zhe and Zhu, Shuhua and Zuo, Ke and Chen, Dacheng and Le, Weibo and Xu, Feng and Wang, Xia},
  title = {Clinical manifestations and prognosis of immune-mediated membranous nephropathy concurrent with other glomerulonephritides: A retrospective Chinese cohort analysis},
  journal = {Clinical Nephrology},
  year = {2025},
  doi = {10.5414/cn111627}
}
Kostenlos starten →